51716-64-4 Usage
General Description
(3aR,5r,6aS)-3-hydroxy-7,7-(ethylidene acetal)bicyclo[3.3.0]octane is a chemical compound with a unique structure consisting of a bicyclic ring system. The compound contains a hydroxy group at the 3a position and an ethylidene acetal moiety at the 7 and 7 positions. The bicyclo[3.3.0]octane framework contributes to the compound's stability and conformational rigidity. (3aR,5r,6aS)-3-hydroxy-7,7-(ethylidene acetal)bicyclo[3.3.0]octane may have potential applications in organic synthesis, medicinal chemistry, or as a building block for the preparation of complex organic molecules. However, further research and studies are needed to fully understand its properties and potential uses in various fields.
Check Digit Verification of cas no
The CAS Registry Mumber 51716-64-4 includes 8 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 5 digits, 5,1,7,1 and 6 respectively; the second part has 2 digits, 6 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 51716-64:
(7*5)+(6*1)+(5*7)+(4*1)+(3*6)+(2*6)+(1*4)=114
114 % 10 = 4
So 51716-64-4 is a valid CAS Registry Number.
51716-64-4Relevant articles and documents
Synthesis and biological evaluation of bicyclo[3.3.0] octane derivatives as dipeptidyl peptidase 4 inhibitors for the treatment of type 2 diabetes
Cho, Tang Peng,Gang, Lin Zhi,Long, Yang Fang,Yang, Wang,Qian, Wang,Lei, Zhang,Jing, Luo Jing,Ying, Feng,Ke, Yan Pang,Ying, Leng,Jun, Feng
body text, p. 3521 - 3525 (2010/08/20)
A series of novel bicyclo[3.3.0]octane derivatives have been synthesized and found to be dipeptidyl peptidase 4 (DPP-4) inhibitors. Compounds 10a and 10b demonstrate good efficacies in oral glucose tolerance tests.
DICYCLOOCTANE DERIVATES, PREPARATION PROCESSES AND MEDICAL USES THEREOF
-
Page/Page column 42, (2009/01/24)
The present invention relates to new dicyclooctane derivates represented by general formula (I), preparation processes and pharmaceutical compositions containing them, and to uses for treatment especially for dipeptidyl peptidase inhibitor (DPPIV), in which each substituent group of general formula (I) is as defined in specification
